Inclusion Criteria:

          -  Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage
             III-IV melanoma starting or continuing adjuvant Pembrolizumab without active evidence
             of disease (NED).

          -  Must be treatment naïve or have had treatment no less than 6 months prior to
             enrollment

          -  18 years or older

          -  Must be able to take pills

          -  ECOG performance status of 0-3

          -  Ability to understand and willingness to sign a written informed consent

          -  Members of all racial and ethnic groups are eligible for this study

        Exclusion Criteria:

          -  History of hypersensitivity reactions attributed to beta-glucan

          -  Patients receiving continuous or other ongoing immunosuppressive therapy

          -  Uncontrolled intercurrent illness including, but not limited to, autoimmune diseases,
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  Any patients who have serious autoimmune toxicity during the study period, or those
             who have disease recurrence during the 6-week study period should be excluded and
             analyzed separately

          -  Patients with mucosal melanoma

          -  Patients with concurrent malignancy or recent history thereof